View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Biomedical Sciences Investment Fund Pte Ltd.
(Last) (First) (Middle)
20 BIOPOLIS WAY
#09-01
(Street)
SINGAPORE 138668
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/12/2006 		3. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 1,480(5) I See Footnote(1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (2) (3) Common Stock 1,479,867(5) (6) I See Footnote(1)
Series B Preferred Stock (2) (3) Common Stock 1,091,321(5) (4) I See Footnote(1)
1. Name and Address of Reporting Person*
Biomedical Sciences Investment Fund Pte Ltd.
(Last) (First) (Middle)
20 BIOPOLIS WAY
#09-01
(Street)
SINGAPORE 138668
(City) (State) (Zip)
1. Name and Address of Reporting Person*
Bio One Capital Pte Ltd.
(Last) (First) (Middle)
20 BIOPOLIS WAY
#09-01
(Street)
SINGAPORE 138668
(City) (State) (Zip)
1. Name and Address of Reporting Person*
EDB Investments Pte Ltd.
(Last) (First) (Middle)
20 BIOPOLIS WAY
#09-01
(Street)
SINGAPORE 138668
(City) (State) (Zip)
Explanation of Responses:
1. Securities owned directly by Biomedical Sciences Investment Fund Pte Ltd. These securities may be deemed to be beneficially owned by Bio*One Capital Pte Ltd. ("BioOne"), the fund manager of BioMedical Science Investment Fund PTE LTD ("BSIF") and EDB Investments Pte Ltd. ("EDB"), the parent company of BSIF and BioOne. Each of BioOne and EDB disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that BioOne or EDB is the beneficial owner of the securities for any purpose, except to the extent of its pecuniary interest therein.
2. Immediately.
3. Not applicable.
4. Reflects the automatic conversion of each share of Series B Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
5. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
6. Reflects the automatic conversion of each share of Series A Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
/s/ Sze Kuan Sim, Authorized Signatory 04/12/2006
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
 Exhibit 24

		STATEMENT APPOINTING DESIGNATED FILER
			  AND
AUTHORIZED SIGNATORY
				  April 12, 2006

	Each of the entities
listed on SCHEDULE A attached hereto
(each a "Reporting Person") hereby
authorizes and designates
 Biomedical Sciences Investment Fund Pte. Ltd.
(the "Designated
Filer"), to prepare and file on behalf of such Reporting
Person
individually, or jointly together with other Reporting Persons,

any and all reports, notices, communications and other documents

(including, but not limited to, reports on Schedule 13D, Schedule
13G,
Form 3, Form 4 and Form 5) that such Reporting Person may
be required to
file with the United States Securities and Exchange
Commission or with
any regulatory body, including United States
 federal, state and
self-regulatory bodies, with respect to the
Reporting Person's ownership
of, or transactions in, the securities
of any entity whose securities are
beneficially owned (directly or
indirectly) by such Reporting Person
(collectively, the "Reports").

	Each Reporting Person hereby further
authorizes and designates
Sze Kuan Sim (the "Authorized Signatory") to
execute and file on
behalf of such Reporting Person the Reports and to
perform any
and all other acts, which in the opinion of a Designated
Filer or
such Authorized Signatory may be necessary or incidental to the

performance of the foregoing powers herein granted.

	The authority
of the Designated Filer and Authorized Signatory under
this document
with respect to each Reporting Person shall continue until
such Reporting
Person is no longer required to file any Reports with respect
to the
Reporting Person's ownership of, or transactions in, securities, unless

earlier revoked in writing.  Each Reporting Person acknowledges that the

Designated Filer and the Authorized Signatory are not assuming any of the

Reporting Person's responsibilities to comply with any United States
federal
or state law or with any regulations promulgated thereto.


SCHEDULE A

BIOMEDICAL SCIENCES INVESTMENT FUND PTE. LTD.
BIO*ONE
CAPITAL PTE LTD.
EDB INVESTMENTS PTE LTD.



	In Witness Whereof,
the undersigned have caused this Statement
Appointing Designated Filer
and Authorized Signatory to be effective
as of April 12, 2006.



Reporting Persons:



April 12, 2006

		BIOMEDICAL SCIENCES
INVESTMENT FUND PTE. LTD.


		By: /s/ Chu Swee Yeok


		Name:
Chu Swee Yeok


		Title: Director




April 12, 2006


		BIO*ONE CAPITAL PTE LTD.

		By:  /s/ Chu Swee Yeok


		Name:
Chu Swee Yeok


		Title: Chief Executive Officer




April
12, 2006

		EDB INVESTMENTS PTE LTD.

		By: /s/ Anna Chan



		Name: Anna Chan


		Title: Director Investments


 Exhibit 99

				JOINT FILER INFORMATION

Joint Filer Name:
Bio*One Capital Pte Ltd.

Relationship to Issuer:	  10% Owner


Address:			    20 Biopolis Way, #09-01 Centros, Singapore 138668


Designated Filer:		   Biomedical Sciences Investment Fund Pte Ltd.


Date of Event
  Requiring Statement:	   April 12, 2006

Issuer Name
and Ticker
  or Trading Symbol:		Vanda Pharmaceuticals, Inc. (VNDA)


Signature			    Bio*One Capital Pte Ltd.

						By: /s/ Sze Kuan Sim

						    -----------------------------------
						    Sze Kuan Sim,
Authorized Signatory



Joint Filer Name:		   EDB Investments Pte
Ltd.

Relationship to Issuer:		 10% Owner

Address:				  20
Biopolis Way, #09-01 Centros, Singapore 138668

Designated Filer:
Biomedical Sciences Investment Fund Pte Ltd.

Date of Event

Requiring Statement:		 April 12, 2006

Issuer Name and Ticker
  or
Trading Symbol:		Vanda Pharmaceuticals, Inc. (VNDA)

Signature				 EDB
Investments Pte Ltd.

						By: /s/ Sze Kuan Sim

- -----------------------------------
						    Sze Kuan Sim, Authorized
Signatory